Interpace Biosciences Holds 2026 Annual Meeting; Approves Charter, Plans

What Happened

• Interpace Biosciences, Inc. (IDXG) filed an 8-K on August 21, 2026 reporting results of its August 20, 2026 annual meeting. Shareholders approved an amended and restated certificate of incorporation and granted the board authority to effect a reverse stock split at a ratio of 1-for-2 to 1-for-10 (board to set exact ratio within one year). Shareholders also approved the 2026 Equity Incentive Plan, the 2026 Employee Stock Purchase Plan, elected five directors, approved a non-binding advisory "say-on-pay" vote, and ratified EisnerAmper, LLP as the company’s auditor for FY2026.

Key Details

• Amended and Restated Certificate of Incorporation: For 24,981,181; Against 246,552; Abstain 3,625; Broker non-vote 1,347,136.
• Board authority for reverse stock split (1-for-2 to 1-for-10): For 26,180,980; Against 397,262; Abstain 252.
• 2026 Equity Incentive Plan approved: For 24,887,762; Against 339,193; Abstain 4,403; Broker non-vote 1,347,136.
• 2026 Employee Stock Purchase Plan approved: For 24,580,773; Against 648,533; Abstain 2,052; Broker non-vote 1,347,136.
• Director elections (all five re-elected): Vijay Aggarwal (For 25,093,904), Thomas W. Burnell (For 25,095,783), Joseph D. Keegan, Ph.D. (For 24,422,783), Fortunato Ron Rocca (For 24,422,706), Stephen J. Sullivan (For 24,422,713). Broker non-votes reported 1,347,136 for these elections.
• Say-on-pay (advisory): For 24,952,970; Against 249,460; Abstain 28,928; Ratification of auditor EisnerAmper, LLP: For 26,442,760; Against 134,660; Abstain 1,074.

Why It Matters

• The board now has shareholder approval to implement a reverse stock split (between 1-for-2 and 1-for-10) if it chooses within one year—an action that would reduce the number of outstanding shares and raise the per‑share price but would not change each shareholder’s proportional ownership. Investors should watch for any future board announcement specifying if and when a split will be implemented and at what ratio.
• Approval of the 2026 Equity Incentive Plan and ESPP authorizes additional equity-based compensation, which can affect future share dilution and executive incentives. Re-election of directors and auditor ratification maintain current governance and oversight continuity.